FibroBiologics Announces Upcoming Phase 1/2 Clinical Trial for Innovative Diabetic Foot Ulcer Therapy at Advanced Wound Care Summit
Reuters
Jul 11, 2025
<a href="https://laohu8.com/S/FBLG">FibroBiologics</a> Announces Upcoming Phase 1/2 Clinical Trial for Innovative Diabetic Foot Ulcer Therapy at Advanced Wound Care <a href="https://laohu8.com/S/SMMT">Summit</a>
FibroBiologics Inc. has announced the upcoming presentation of their recent research advances at the Advanced Wound Care Summit USA in Boston, Massachusetts. The company's Founder and CEO, Pete O'Heeron, is set to present on July 15, 2025, focusing on fibroblast-based technology for wound healing and psoriasis. The presentation will highlight FibroBiologics' CYWC628 therapy, which represents a novel approach to treating diabetic foot ulcers by leveraging the body's natural regenerative processes. This therapy is part of their Phase 1/2 clinical trial, which is scheduled to begin later this year. The summit will feature various industry leaders discussing innovations in wound care and is an opportunity for FibroBiologics to showcase their potential contributions to the field. Results of the clinical trial have not yet been presented as the trial is still in preparation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9492657-en) on July 11, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.